Connect with us


Industry entrepreneurs predict 2022 CBD trends

As we get ready to welcome another year, we ask CBD industry insiders to predict what 2022 holds for the sector.



As we get ready to welcome another year, we ask CBD industry insiders to predict what 2022 holds for the sector.

This year has been a difficult one for businesses but especially those in the CBD space. As well as navigating the novel food regulations, there have been supply issues, shipping problems, lockdowns and Covid-19 restrictions. Now that we have vaccines yet new strains, new regulations and also the publication of the Novel foods list coming in the new year, we ask:

What’s next for 2022?

We asked a few cannabis and CBD brands where they see the industry heading next year and what opportunities, or difficulties, to expect.

Fergus Kerrigan founder of Ethos CBD : European consolidation and the Irish market

Irish brand Ethos CBD was founded by Fergus Kerrigan and Amy O’ Flaherty in 2020. They offer a range of CBD oils, tea and they have recently moved into the topicals market with the creation of a new balm.

Fergus said: “When it comes to Europe, we believe there will be greater consolidation in the CBD industry with the number of brands reducing, but the overall quality of products going up. This will be spurred on by stricter regulatory conditions and by increased customer knowledge on what represents quality. Customers will demand functional products that help their individual wellbeing needs.”

When it comes to the Irish market, he explained that Ireland has been slower to adopt CBD but it’s getting there:

“Ireland has been a much slower adopter of CBD than the UK, however, we have noticed a tipping point in the customer perception of CBD. The conversation is much more open and educated and it’s getting wider coverage from the quality press. This is a positive sign for the growth and adoption of CBD products however there are key challenges, mainly poor contradictory regulation and lack of investment in hemp farming.”

Marc Burbidge, CEO of B3 labs: Terpenes in CBD and a boost for the drinks industry.

When it comes to industry trends for next year, Marc believes it will be the year where terpenes and blends become important, along with CBG.

“When I came into the industry, it was all about herbs, terpenes and different cannabinoids for me. When I spoke about this, people looked at me like I was a bit odd but this is exactly what’s happening now.

“Another key area will be the innovation in encapsulations, increased bioavailability and potentially more growth in the drinks. That’s where I see the industry wanting to go, but whether the regulatory framework will allow it to go there is another question.”

Danny Purton of Herbotany Health: on the public list.

Danny predicts that the public list will cause some uncertainty for brands which should last well into 2022.

“The big one for the industry is the public list. Whoever is on the public list, then their products will have a pathway to show they are safe as the efficacy will be what it says on the bottle. There will definitely be an industry acclimation for CBD brands where some will miss out, some will have to start the process from scratch or get help from other companies.

Danny also hopes to see more freedom with what brands can and cannot say about CBD.

“I’ve had a number of clients come to me who have had really bad times with Covid or have debilitating long Covid symptoms. They take CBD and say to us that it changed their life in terms of improvements. These are the stories we love and why we went into CBD but we can’t tell the public and that’s so frustrating.”

Predicts: Natalie from Empwr Botanics

Natalie Meredith, Founder of Empwr Botanics: CBD in skincare

Natalie predicts that more of the big brands will be adding CBD to their main ranges.

“One trend I’ve noticed is skincare. I see big companies starting to put CBD into their skincare range like Body Shop, Boots or Superdrug so it’s definitely catching on.

“Until the FSA decide to approve some applications for oils and other products, there are going to end up being a few stand out companies who have the money to advertise. Those who have the resources are going to be the stand out ones when it comes to anything consumable like oils or capsules.”

She also sees CBD playing a bigger part in wellness based on the American industry.

“I think CBD is going to go in a positive direction but it will be a struggle to find better ways to regulate it. It will become easier and a normal lifestyle thing rather than a trend everyone is jumping on. If America is any blueprint to go off then it will be a lifestyle thing where everyone says, ‘of course, I take CBD, don’t you?'”

Jeff Chen, Radicle Science: on the US outlook and growth in minor cannabinoids

Jeff predicts that there will be a call for more clarity around CBD in the US.

“One big development is the call for regulatory clarity in the US. CBD sits in a limbo where people are selling it but the FDA keeps saying you can’t sell this and it needs to be [classed as] a pharmaceutical drug. It has prevented major retailers from selling CBD and interfered with banking, credit card processing, even advertising. That’s really unfortunate. There needs to be more clarity.”

He added: “I know a congressional member has tried to pass bills, so who knows when this clarity is going to come or if the regulation is going to be stricter or less strict than it is now. The regulatory clarity is something I hope we see in 2022.

Jeff also highlighted the growth in minor cannabinoids.

“There is a growing amount of interest in the minor cannabinoids. People are starting to talk about CBG and CBC or even Delta-8 THC. People are finally thinking beyond THC or CBD to the world of the multiple cannabinoids that are available. Now thanks to demand, people are starting to breed different strains that produce cannabinoids.  Normally they are found in such small amounts in the plant that people are genetically engineering microbes that can effectively produce these minor cannabinoids.”

Predicts: A box of DNA CBD

David Molloy, founder of DNA CBD: CBD education and CBD isolate

David predicts that the industry will see more scientific evidence come to light, and also a growth in CBD isolate on the market.

“I think there will be an increasing number of health practitioners intrigued about the burgeoning evidence surrounding CBD and its constituents as a whole plant and as a safe and well-tolerated supplement. Education will be on the rise which will be great for the industry and the communities at large, and with that a move from CBD being a last resort to consider a practical first response.

“We have already seen a huge trend due to regulation towards a reductionist health approach with more CBD isolate on the market. It will be important for customers to appreciate that these are six to 10 times less potent, mix easier with medications and are harder to acquire the effective dose. I feel we should be ensuring choice that reflects the growing nutritional movement of gut diversity, whole foods and therefore whole plant CBD in line with this global trend especially considering its heightened safety profile and potency.”

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Cannabis Trades Association now under new leadership

The UK Cannabis Trades Association has appointed a new executive director.



Cannabis Trades Association now under new leadership
Home » Leadership » Industry entrepreneurs predict 2022 CBD trends

The Cannabis Trades Association (CTA) has appointed Marika Graham-Woods as its new executive director.

Graham-Woods was voted in by the CTA board in November as executive director. 

The trade body is Europe’s largest representing the interests of the cannabis and hemp industry, and the only Association formed to work with Government to create a legal and sustainable European cannabis industry.

Graham-woods brings specialist experience in strategic international marketing and market development as well as business growth and change leadership.

The CTA stated: “Over the last year we have become an outward looking organisation which exists to support our members, and their businesses by opening up the Hemp and Cannabis Markets in the UK, EU and further afield.

“The UK markets are set to open rapidly with legislative changes during 2022. The CTA is at the centre of these changes helping to remove the legal barriers to hemp and cannabis markets and enact legislative change.”

Speaking in a public post, Graham-Woods, stated: “I am the new Executive Director for the CTA, and together with my fellow Executive Director Sian Phillips we are changing the CTA together. I was elected to my role at the end of November…

“The CTA is forming the Industrial Hemp Marketing Board to organise and market growers, production facilities and the products that vertical integrated markets needs eh building materials and bio-fuels.”

In July 2021, the body struck a deal with a local UK authority, Oxfordshire County Council, to help it navigate regulations – a relationship is known as a primary authority partnership.

The partnership was formed due to Novel Food regulations on CBD products  – for which the Foods Standards Agency, recently announced local authorities will need to ramp up efforts of enforcement as applications make their way through the approval process. 

Continue Reading


“Every milestone we go through as a business gives me a moment of pride.”

Matthew Anderson shares his journey from marketing to the CBD wellness space with the launch of his new business, RAIN.



RAIN: CBD pens

Matthew Anderson, managing director of RAIN speaks to Cannabis Wealth about his start in the CBD industry.

Matthew was inspired to enter the CBD industry after it was recommended to him during a stressful period in his life. As he began to feel more relaxed, he wondered if there was a way he could combine his marketing skills with wellness products.

“I tried CBD after a friend gave it to me to help me with how stressful things were at the time. I had no experience with CBD and zero knowledge about it other than it was related to cannabis. It blew me away and I was surprised by how much it helped me,” he said.

“That was the beginning of my curiosity on a purely personal level. I began to realise that the career I was in wasn’t sustainable in a lot of ways. I had been interested in wellness and the area of CBD was becoming something I was interested in.”

By chance, Matthew was introduced to Harry Jameson, the personal trainer and wellness consultant. Together they developed the idea for RAIN. The brand launched in 2021 with a selection of three products including their RAIN cloud CBD pen, a balm and a candle. The candle is described as containing a “fragrance contains only non-synthetic essential oils which evoke delicious notes of the cannabinoid sensory experience… without unnerving the neighbours.”

RAIN founder Matthew


Matthew explained the reason behind the name. “We liked it as it is symbolic of renewal. Cleanse the old and tend the new is our line which is what rain does. It embraces the natural world which is what the brand is about. Everything we do is 100 per cent natural in terms of ingredients in our products, even our pens.”

The signature product for the brand is their CBD pen which contains 40 per cent of high-quality broad-spectrum CBD with a carefully selected array of terpenes. The pen has a citrus flavour and contains terpenes such as linalool, citral and terpinolene. The pen design is sleek and it can fit easily into a pocket or handbag.

“Our RAIN CLOUD sums up the real essence of the opportunity we saw. On a formulation level, we saw the chance to make a product that is genuinely cleaner than others by using the best ingredients. The vape industry was lacking an elegant beautiful device as vapes were traditionally clunky, big devices.”

RAIN: A CBD candle from the company RAIN

Marketing RAIN

With his background in marketing, Matthew has a head start on how to position the brand or advertise. But, the CBD industry is a difficult one to advertise in due to restrictions and now, social media bans.

Matthew said: “Social media is not our friend in the way it is to a lot of brands at our stage. It is the go-to marketing channel for early-stage consumer business and there is no getting around that. We would like it to be for us as well and we can do that but to a very limited extent. We can’t put any money behind paid marketing on a lot of platforms.”

He added: “It can be incredibly frustrating when you are trying to figure out a strategy, how to scale or grow your business. You may not have the money to put into traditional advertising channels and PR isn’t a cheap thing to do either.”

RAIN: CBD balm

As with a lot of brands, the changing nature of the CBD industry has had an impact on the products Matthew and Harry have decided to launch. The novel foods regulations have meant they decided not to launch an oil.

“The novel foods regulations have been the biggest headache for the business. We would have had a sublingual oil on the market were it not for that regulation. It has been a big frustration for us. We refocused what we wanted to do and hopefully one day we can make a product like that.”

RAIN is Matthew’s first business and as a result, he feels incredibly proud about what he has achieved. He has been delighted by the success of the business but feels that the reaction from customers has made it even more worthwhile

“As it’s my first business, every achievement is cool. The fact that people wanted to put their hard-earned money into the business I run is something in itself. Then there is having a business which is on the shelves in shops, including Selfridges as well, he said.

“The most meaningful thing has been the customers who love the products. The feedback has been phenomenal. We really believe in our products like our balm. We’ve had people find it incredibly useful for things like arthritis and I use it when I play tennis.”

“On a professional level, just about every milestone, we go through as a business gives me a moment of pride.”

Continue Reading


Productive start to 2022 for Apollon Formularies

The company has secured new agreements, confirmed the renewal of licenses and has appointed a new non-executive director.



Productive start to 2022 for Apollon Formularies

After ending 2021 initiating the treatment of cancer patients in Jamaica, UK-based Apollon Formularies has continued with a productive start to 2022.

International medical cannabis company Apollon Formularies has announced the appointment of Roderick Claude McIllree as a non-executive director of the company.

McIllree, who was instrumental in bringing the company to the AQSE Growth Market via a reverse takeover in April 2021, has advised, funded and run public companies across multiple global exchanges in several sectors for more than 20 years. He has specific experience in technology, mining, international logistics and finance.

The news follows announcements across January 2022, including the renewal of its licenses in Jamaica which will enable the company to operate its new pharmaceutical processing laboratory, as well as to operate consumer dispensaries and provide spa services. It also announced the signing of new agreements with Jamaica’s Cannabis License Authority (CLA) licensed cultivators allowing access to high-quality flower, working with Jamaican farmers.

CEO of Apollon, Stephen Barnhill, MD, commented: “We are delighted to welcome Rod to the Board as a non-executive director.”

McIllree currently owns ordinary shares in the Apollon, representing approximately 29.06 per cent of the issued share capital.

“Rod, a significant shareholder in the company, has a long-established career with a demonstrable record of growing small-cap companies and creating shareholder value of many business ventures over a long career,” continued Barnhill.

“He brings a wealth of financial and directorial experience to the team, and I look forward to working with him as we move our business towards the global rollout of Apollon’s product range and medical expertise to supportive jurisdictions.”

Currently charmian of AIM-listed Bluejay Mining Plc., McIllree has been a long-time advisor to, and investor in, Apollon. The company has stated that it believed his appointment strengthens its board at a time that the company expects to experience significant growth.

In July 2021, Apollon announced results of third-party independent testing of its medical cannabis formulations, which demonstrated they were effective in killing hormone-resistant and hormone-sensitive prostate cancer cells in 3D cell cultures. 

McIllree commented: “Apollon is an excellent example of utilising research and development to help improve people’s lives. 

“The compelling results of Apollon’s formulations killing cancer cells in 3D-cell culture and the upcoming opening of the International Cancer and Chronic Pain Institute in Jamaica are important milestones for the company and offers outstanding potential on many fronts. 

“I look forward to working with Dr Barnhill and the wider Apollon team at this exciting time for growth as the company looks to execute on the various business partnership opportunities becoming available.”

Apollon expects to appoint further high-profile directors to the board in the coming month.

Continue Reading
Sign up for the Cannabis Wealth newsletter

Recent Posts